All manuscripts
Publications CAR T Cells

Non-viral chimeric antigen receptor (CAR) T cells going viral

Published Journal Immuno-Oncology and Technology

Share
10 pages Non-viral chimeric antigen receptor (CAR) T cells going viral

Overview

This review presents transposon/transposase systems and CRISPR/Cas9 knock-in as cheaper, more flexible alternatives to viral vectors for CAR T production, with low knock-in efficiency as the main obstacle. It also sets out how manufacturing has to adapt to electroporation, and the genotoxicity testing that comes with it.

What this paper found

Non-viral methods for producing CAR-T cells, based on transposon/transposase systems and CRISPR/Cas9 knock-in, are presented as cheaper and more flexible alternatives to viral vectors, although low knock-in efficiency remains the main obstacle. The review describes how manufacturing must change to accommodate electroporation, including larger starting and expansion volumes, new cultivation vessels, automated cell washing and enrichment platforms, and a final purification step by surface marker or drug selection. It also covers quality control for genotoxicity, from insertion-site mapping to off-target and translocation detection, prompted by lymphomas in 2 of 10 patients treated with PiggyBac-modified cells in the CARTELL trial.

Note: This is a narrative review; it summarizes published work and reports no new experiments.

Non-viral delivery platforms present a promising alternative to address the limitations associated with viral delivery in CAR-T cell therapies. — H. Balke-Want, V. Keerthi, A. Cadinanos-Garai, C. Fowler, N. Gkitsas, A.K. Brown, R. Tunuguntla, M. Abou-el-Enein, S.A. Feldman, Immuno-Oncology and Technology

Study details

Authors
H. Balke-Want, V. Keerthi, A. Cadinanos-Garai, C. Fowler, N. Gkitsas, A.K. Brown, R. Tunuguntla, M. Abou-el-Enein, S.A. Feldman
Institution
Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, USA · USC/CHLA Cell Therapy Program, University of Southern California, and Children's Hospital Los Angeles, Los Angeles, USA · Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
Journal
Immuno-Oncology and Technology
Year
2023
PMID / PMC
PMID: 37124148 · PMC
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy · Solid tumor

Explore related

Full citation

Balke-Want H, Keerthi V, Cadinanos-Garai A, et al. Non-viral chimeric antigen receptor (CAR) T cells going viral. Immunooncol Technol. 2023;18:100375.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →